Announcements Trials
Browse Landscape

Status

Completed 5Active not recruiting 4Recruiting 2Terminated 1Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 2

Study Type

Interventional 9Observational 2

Sponsor

Cancer Type

Thoracic 2Other 1

Conditions

Sexual Dysfunction, Physiological 1Eunuchism 1Erectile Dysfunction 1Carcinoma, Non-Small-Cell Lung 1ALK-positive Non-small Cell Lung Cancer 1

Interventions

Blood Specimen Collection 123Surveys and Questionnaires 82Observation 49Radiotherapy 40Surgical Procedures, Operative 34Drug Therapy 34Biopsy 31Specimen Handling 28Data Collection 27Watchful Waiting 20Interviews as Topic 20Magnetic Resonance Imaging 18Immune Checkpoint Inhibitors 17Liquid Biopsy 16Magnetic Resonance Spectroscopy 15Immunotherapy 15Standard of Care 13pembrolizumab 12Tomography, X-Ray Computed 12Ultrasonography 11trastuzumab deruxtecan 10lenvatinib 10Radiosurgery 10Nivolumab 10Neoadjuvant Therapy 10Carboplatin 10Tissue Banks 9Restraint, Physical 9Radiation 9Endoscopy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Observational × lorlatinib × Clear all
NCT06532149 2024-08-09

EROS

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Recruiting
80 enrolled
OtherThoracic

Carcinoma, Non-Small-Cell Lung, Eunuchism, Erectile Dysfunction, Sexual Dysfunction, Physiological

NCT06361589 2024-04-12

Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients

Sichuan Cancer Hospital and Research Institute

Recruiting
200 enrolled
Thoracic

ALK-positive Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡